NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Petco Health and Wellness Company, Inc. (“Petco” or the “Company”) (NASDAQ:WOOF) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired Petco securities between January 14, 2021 and June 5, 2025, both dates inclusive (the “Class P ...

Core Viewpoint - Nvidia's stock price is targeting a record high of $200, supported by strong fundamentals in the growing artificial intelligence market and a bullish technical outlook [1][5][6]. Group 1: Stock Performance - Nvidia's stock closed at $180.45, down 0.8% on the day, but remains up 30% year-to-date [1]. - The stock has been trading in a strong "channel up" formation since early April, indicating a bullish trend [3]. - Historical analysis shows that Nvidia's last three bullish legs each delivered gains of at least 20%, suggesting potential for similar future gains [4]. Group 2: Technical Analysis - The 50-day moving average has provided strong support since May, confirming buyer control and facilitating new rallies [3]. - The relative strength index (RSI) must hold its support for the stock to continue its upward momentum towards the $200 target [4]. Group 3: Fundamental Analysis - Nvidia faced a 30% decline in 2025 due to tariffs and competition from China but has rebounded due to strong demand for GPUs and data centers driven by tech giants' infrastructure spending [5]. - The company is expanding into robotics, autonomous driving, and quantum computing, indicating that the AI opportunity is broader than many investors expect [5]. Group 4: Upcoming Events - Nvidia's Q2 earnings report on August 27 will be critical, particularly regarding revenue performance and demand for products like Blackwell, which could influence the stock's ability to reach the $200 milestone [6].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended to treat Duchenne muscular dystrophy [1][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing gene therapies, specifically ELEVIDYS for Duchenne muscular dystrophy [3]. Allegations - The lawsuit claims that Sarepta made materially false and misleading statements about ELEVIDYS, leading investors to believe it was a safe therapy with no hindrances to broader application approval [3]. - Specific allegations include: - ELEVIDYS posed significant safety risks to patients [3]. - Trial protocols failed to detect severe side effects [3]. - Adverse events from ELEVIDYS treatment led to a halt in recruitment and dosing, attracting regulatory scrutiny [3]. - Positive statements made by the company lacked a reasonable basis due to undisclosed material adverse facts [3]. Stock Price Impact - Following a safety update on March 18, 2025, where a patient died after treatment with ELEVIDYS, Sarepta's stock price fell by $27.81 (27.44%) to close at $73.54 [4]. - On April 4, 2025, after the company disclosed regulatory requests for a review of the death, the stock price dropped by $4.18 (7.13%) to close at $54.43 [4]. - A second patient death reported on June 15, 2025, caused the stock to plummet by $15.24 (42.12%) to close at $20.91 [4]. - Following an FDA Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks, the stock fell by $1.52 (8.01%) to close at $17.46 [4].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of Wegovy® and its collaboration with Novo Nordisk [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which posed risks to patient safety [3]. - It is claimed that the company's positive statements about its business and prospects were materially misleading due to undisclosed risks regarding its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims - The complaint specifies that Hims failed to disclose that its communication with Novo Nordisk was not as beneficial as portrayed, potentially jeopardizing the long-term collaboration for access to Wegovy [4]. - It is alleged that Hims misrepresented the approval of its compounded semaglutide products by Novo Nordisk, which could mislead investors about the company's product offerings [4]. - The lawsuit highlights that Hims made positive statements about its partnership with Novo, which were not supported by the actual circumstances surrounding the collaboration [4].

Group 1 - Innovative Industrial Properties (IIPR) is popular among investors due to its generous dividend yield and focus on properties used for cannabis cultivation [1] - The investment group European Small Cap Ideas offers exclusive access to actionable research on appealing Europe-focused investment opportunities, emphasizing high-quality ideas in the small-cap space [1] - The European Small Cap Ideas portfolio includes two model portfolios: the European Small Cap Ideas portfolio and the European REIT Portfolio, along with weekly updates and educational content [1]

Core Viewpoint - A class action lawsuit has been filed against Reddit, Inc. for alleged misleading statements regarding user traffic and advertising revenue, particularly in relation to changes in Google Search's algorithm and AI features [1][3][5]. Group 1: Lawsuit Details - The lawsuit covers individuals who purchased Reddit securities between October 29, 2024, and May 20, 2025, with a deadline of August 18, 2025, to apply as lead plaintiff [1]. - The complaint alleges that Reddit's user traffic was significantly impacted by changes in Google Search, which began implementing new AI capabilities that altered search results [2][3]. Group 2: Financial Impact - Reddit reported three consecutive quarters of deceleration in daily active user growth in its earnings release on May 1, 2025, leading to a stock price drop of $4.96, or 4.2%, from $118.79 to $113.83 per share [4]. - Following a downgrade by Wells Fargo on May 19, 2025, Reddit's stock fell by $5.24, or 4.6%, from $113.23 to $107.99 per share, with analysts citing permanent disruptions from Google Search's new AI features [5]. - On May 21, 2025, Baird analysts downgraded Reddit's stock again, reducing the price target to $120 from $140, resulting in a further decline of $9.79, or 9.3%, from $105.64 to $95.85 per share [6][7].

Core Insights - JR Research is recognized as a top analyst in technology, software, and internet sectors, focusing on growth and GARP strategies [1] - The investment approach emphasizes identifying attractive risk/reward opportunities with robust price action to generate alpha above the S&P 500 [1][2] - The investment group Ultimate Growth Investing specializes in high-potential opportunities across various sectors with a focus on strong growth potential and contrarian plays [3] Investment Strategy - The strategy combines sharp price action analysis with fundamentals investing, avoiding overhyped stocks while targeting battered stocks with recovery potential [2] - The investment outlook is typically 18 to 24 months for the thesis to materialize, aiming for robust fundamentals and attractive valuations [3] Target Audience - The group is designed for investors looking to capitalize on growth stocks with strong fundamentals, buying momentum, and turnaround plays [3]

Core Viewpoint - Shopify is experiencing a recovery from the COVID-19 pandemic bubble, with stock performance showing a significant increase over the past year but still below all-time highs [2][6][16] Company Performance - Shopify's stock is down 15% from its all-time highs during the pandemic, but it has increased over 100% in the last 12 months [2] - The company reported a 31% year-over-year revenue growth in the last quarter, with strong growth expected for the remainder of the year [6] - Profit margins remain robust, with free cash flow margins at 16% for the quarter, contributing to the stock's rise [6] Market Expansion - Shopify is expanding its international presence, having dominated the North American market [4] - The European division saw a 42% growth in payment volume last quarter, indicating strong international demand [5] Product Innovation - Shopify is continuously adding new commerce tools and features, such as advertising and the Shop Pay application, which are expected to drive future growth [7] - The introduction of AI services like Sidekick and Magic aims to enhance customer engagement and retention within the Shopify ecosystem [9] Payment Solutions - Shopify is expanding its payment options to include stablecoins like USDC, facilitating cross-border transactions and enhancing the shopping experience [10] Future Projections - Revenue growth is projected to exceed 20% for the rest of 2025, with total revenue reaching $10 billion over the last 12 months [13] - If Shopify maintains an average growth rate of 15% over the next five years, revenue could reach $20 billion by 2030, with potential net earnings of $4 billion annually [15] Valuation Concerns - Shopify's current market cap stands at $187 billion, leading to a forward P/E ratio of 47 based on projected earnings growth, suggesting caution for potential investors [16]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of CTO Realty Growth, Inc. securities, alleging misleading statements and unsustainable dividend practices during the Class Period from February 18, 2021, to June 24, 2025 [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that CTO Realty Growth made false and misleading statements regarding the sustainability of its dividends and the profitability of its Ashford Lane property [5]. - The lawsuit alleges that CTO Realty Growth used deceptive practices to artificially inflate its Adjusted Funds from Operations (AFFO), leading to overstated business and financial prospects [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2][3]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by October 7, 2025, to represent other class members in the litigation [1][3]. - No class has been certified yet, meaning investors are not represented unless they retain counsel [7]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its leadership in securities class action settlements and has consistently ranked among the top firms in this area since 2013 [4].

Group 1: Market Overview - A new wave in the technology sector is emerging, focusing on the necessity of building new infrastructure to support increased electricity demand from data centers and AI capabilities [1][2] - The onshoring of artificial intelligence in the U.S. is driving the need for enhanced energy infrastructure to meet the demands of cloud computing and AI model training [2] Group 2: Company Insights - DuPont de Nemours Inc. is highlighted as a key player in the construction of data centers, with its products being essential for industrial applications in infrastructure projects [3][5] - DuPont's stock is currently trading at 78% of its 52-week high, presenting a significant opportunity for recovery as it approaches historically proven valuation levels [4] - Vanguard Group increased its holdings in DuPont by 1.6%, bringing their total position to $3.3 billion, indicating strong investor confidence [6] - Analysts have a consensus Moderate Buy rating for DuPont, with a price target of $88.3 per share, while some analysts project a higher valuation of $94 per share, suggesting a potential rally of about 35% [7][8] Group 3: Caterpillar Insights - Caterpillar Inc. is positioned as a critical player in new infrastructure buildouts, with a current stock price that reflects bullish sentiment [9][10] - The consensus rating for Caterpillar is also Moderate Buy, with a fair value estimate of $444 per share, while some analysts project a valuation exceeding $500 per share, indicating a potential upside of approximately 27% [11] - Short interest in Caterpillar has declined by 8.3% over the past month, signaling a shift in market sentiment regarding the demand for data center construction [12] Group 4: Martin Marietta Insights - Martin Marietta Materials is essential for commercial construction, trading at 95% of its 52-week high, reflecting its role in the early stages of infrastructure projects [14][16] - Analysts currently rate Martin Marietta as a Moderate Buy with a fair value of $620.8 per share, while some see it valued at $700 per share, suggesting a potential upside of 16.6% [16][17] - Geode Capital recently built a position worth $831.3 million in Martin Marietta, indicating strong institutional interest [17]